UA42779C2 - Фармацевтично стійкий препарат оксалату платини для парентерального застосування - Google Patents

Фармацевтично стійкий препарат оксалату платини для парентерального застосування

Info

Publication number
UA42779C2
UA42779C2 UA97010366A UA97010366A UA42779C2 UA 42779 C2 UA42779 C2 UA 42779C2 UA 97010366 A UA97010366 A UA 97010366A UA 97010366 A UA97010366 A UA 97010366A UA 42779 C2 UA42779 C2 UA 42779C2
Authority
UA
Ukraine
Prior art keywords
platinum oxalate
parenteral application
pharmaceutical
resistant preparation
oxalate
Prior art date
Application number
UA97010366A
Other languages
English (en)
Russian (ru)
Inventor
Хуссам Ібрагім
Хуссам Ибрагим
Ролланд-Івс Мовернай
Ролланд-Ивс Мовернай
Original Assignee
Дебіофарм С.А.
Дебиофарм С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50845249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA42779(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дебіофарм С.А., Дебиофарм С.А. filed Critical Дебіофарм С.А.
Publication of UA42779C2 publication Critical patent/UA42779C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Фармацевтично стійкий препарат оксалату платини для парентерального застосування містить розчин оксалата платини у воді при концентрації від 1 до 5 мг/мл та рН від 4,5 до 6,0. Після зберігання протягом фармацевтичного припустимого терміну вміст оксалату платини рівний найменше 95 % від початкового вмісту і розчин зберігається чистим, безбарвним і вільним від осаду.
UA97010366A 1994-08-08 1995-08-07 Фармацевтично стійкий препарат оксалату платини для парентерального застосування UA42779C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH246294 1994-08-08
PCT/IB1995/000614 WO1996004904A1 (fr) 1994-08-08 1995-08-07 Preparation pharmaceutiquement stable d'oxaliplatine

Publications (1)

Publication Number Publication Date
UA42779C2 true UA42779C2 (uk) 2001-11-15

Family

ID=50845249

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97010366A UA42779C2 (uk) 1994-08-08 1995-08-07 Фармацевтично стійкий препарат оксалату платини для парентерального застосування

Country Status (17)

Country Link
US (1) US5716988A (uk)
EP (1) EP0774963B1 (uk)
JP (1) JP3547755B2 (uk)
KR (1) KR100365171B1 (uk)
CN (1) CN1138541C (uk)
AT (1) ATE197249T1 (uk)
AU (2) AU2989695A (uk)
BR (1) BR9508554A (uk)
CA (1) CA2196922C (uk)
CZ (1) CZ286714B6 (uk)
DE (1) DE69519300T2 (uk)
DK (1) DK0774963T3 (uk)
ES (1) ES2152412T3 (uk)
IL (1) IL114852A (uk)
RU (1) RU2148400C1 (uk)
UA (1) UA42779C2 (uk)
WO (1) WO1996004904A1 (uk)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100365171B1 (ko) 1994-08-08 2003-02-19 드바이오팜 에스.아. 약학적으로안정한옥살리플라티늄제제
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
AU762138B2 (en) * 1998-10-14 2003-06-19 Debiopharm S.A. Oxaliplatinum preparation packaging
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
BRPI0013613B8 (pt) * 1999-08-30 2021-05-25 Debiopharm Sa composição farmacêuticamente estável de oxaliplatina para administração parenteral.
US7070796B1 (en) * 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
US7012072B2 (en) * 2000-12-12 2006-03-14 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
EP1368022B1 (fr) * 2001-03-02 2007-06-20 Debiopharm S.A. Utilisation d'un flacon contenant une solution d'oxaliplatine
WO2003004505A1 (en) * 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
WO2005020980A1 (en) * 2003-08-28 2005-03-10 Mayne Pharma Pty Ltd Acid containing oxaliplatin formulations
JP2007512318A (ja) * 2003-11-25 2007-05-17 プラトコ・テクノロジーズ・（プロプライエタリー）・リミテッド 白金（ｉｉ）錯体並びに該錯体の製法及び使用
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
AU2005251588B2 (en) * 2004-06-09 2009-01-08 Taiho Pharmaceutical Co., Ltd. Antitumor effect fortifier, antitumor agent and method of therapy for cancer
CN101018797A (zh) 2004-09-01 2007-08-15 普拉托技术（私有）有限公司 铂(ⅱ)配合物的制备
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2007029268A2 (en) 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
KR20080096682A (ko) * 2006-01-30 2008-10-31 플라트코 테크놀로지스 (프로프라이어터리) 리미티드 백금(ⅱ) 착물의 제조법
CN101442998B (zh) * 2006-03-16 2012-03-14 比奥纽默里克药物公司 抗癌活性加强化合物和制剂及其用法
BRPI0711385A2 (pt) 2006-05-09 2011-11-08 Novartis Ag combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso
MX2009007597A (es) * 2007-01-18 2009-07-22 Merck Patent Gmbh Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
WO2009087660A1 (en) * 2007-11-12 2009-07-16 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
WO2009113983A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
WO2009113989A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
JP5759464B2 (ja) 2009-09-21 2015-08-05 ジェイダブリュー ファーマシューティカル コーポレイション オキサリプラチンのナノ粒子及びその製造方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2013202575B1 (en) * 2012-01-04 2013-05-16 Hospira, Inc. Dexmedetomidine premix formulation
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP5314790B1 (ja) * 2012-07-09 2013-10-16 東和薬品株式会社 オキサリプラチン含有医薬組成物
SG10201701063WA (en) 2012-08-10 2017-04-27 Taiho Pharmaceutical Co Ltd Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
CN103690494B (zh) * 2013-11-29 2015-04-15 杭州华东医药集团新药研究院有限公司 一种低杂质含有奥沙利铂的组合物及其制备方法
CN106659706B (zh) 2014-06-23 2020-03-20 普莱康治疗有限公司 铂化合物、组合物及其用途
SI3865484T1 (sl) 2015-07-07 2024-05-31 H. Lundbeck A/S Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni
CN104940151A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种抗癌药物奥沙利铂冻干粉针剂组合物
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) * 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
US10987353B2 (en) 2016-05-04 2021-04-27 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
WO2018009424A1 (en) 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
PT3630772T (pt) 2017-05-26 2024-02-05 Cardurion Pharmaceuticals Inc Métodos para fabricar e usar inibidores de pde9
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
NL8901433A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Carboplatinpreparaat.
JPH04185601A (ja) * 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
AU5416394A (en) * 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
KR100365171B1 (ko) 1994-08-08 2003-02-19 드바이오팜 에스.아. 약학적으로안정한옥살리플라티늄제제

Also Published As

Publication number Publication date
EP0774963A1 (fr) 1997-05-28
US5716988A (en) 1998-02-10
CN1154654A (zh) 1997-07-16
IL114852A0 (en) 1995-12-08
WO1996004904A1 (fr) 1996-02-22
JP3547755B2 (ja) 2004-07-28
CN1138541C (zh) 2004-02-18
EP0774963B1 (fr) 2000-11-02
BR9508554A (pt) 1997-11-25
ATE197249T1 (de) 2000-11-15
DE69519300T2 (de) 2001-05-31
KR970704434A (ko) 1997-09-06
RU2148400C1 (ru) 2000-05-10
JPH10508289A (ja) 1998-08-18
CZ286714B6 (en) 2000-06-14
ES2152412T3 (es) 2001-02-01
DK0774963T3 (da) 2001-01-29
AU2252499A (en) 2000-03-23
CA2196922C (fr) 2004-06-01
AU2989695A (en) 2000-03-07
KR100365171B1 (ko) 2003-02-19
CA2196922A1 (fr) 1996-02-22
DE69519300D1 (de) 2000-12-07
IL114852A (en) 2000-02-29
AU731981B2 (en) 2001-04-12
CZ37997A3 (en) 1997-06-11

Similar Documents

Publication Publication Date Title
UA42779C2 (uk) Фармацевтично стійкий препарат оксалату платини для парентерального застосування
KR900015737A (ko) 배합물
EP0758895A4 (en) DOSAGE FORMS AND METHOD FOR IMPROVING ERECTILE DYSFUNCTION IN MEN
NZ324446A (en) Pharmaceutical composition containing (e)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropyl-quinolin -3'-yl]-6-heptenoic acid where the aqueous solution or dispersion of the composition has a ph of 7 to less than 8
DE3872666D1 (de) Schmiermittelzusammensetzung zur verminderung des brennstoffverbrauchs.
JPS6490123A (en) Nitroglycerol spray agent
ES2048588T3 (es) Composicion bebible baja en calorias.
ES8306321A1 (es) Un procedimiento para la produccion de un preparado en crema antiinflamatorio.
KR890000085A (ko) 필수지방산 합성물(Essential Fatty Acid Compositions)
HUT40324A (en) Gargling the mouth liquid for preventing formation of dental deposits
EP0736033A4 (en) NOVEL MIXTURES OF THERAPEUTIC CARBON HYDRATES TO RELIEVE PREMENSTRUAL SYNDROME
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
DE68911501D1 (de) Analgetische antacide Brausezusammensetzung mit reduziertem Natriumgehalt.
BG103306A (en) Liquid allendronate compositions
AR245591A1 (es) Una composicion oral estable, con propiedades antiplaca y antigingivales mejoradas.
NZ334949A (en) Stabilised pharmaceutical composition of quinupristine and dalfopristine with methanesulphonic acid or hydrochloric acid
IL127851A0 (en) Inhibition of TNF activity
BR9813114A (pt) Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf
Viswaranjan et al. Effect of tannic acid on the protein, carbohydrate and lipid levels in the tissues of the fish Oreochromis mossambicus.
FR2512831B1 (fr) Compositions contenant des esters utiles pour reduire la consommation de combustible et leur application
ATE156334T1 (de) Psyllium enthaltende zusammenstellungen für getränke ohne geschmackstoffe
DE3851325D1 (de) Gegen den Zellmembransynthese-Inhibitor resistente Mutante und Verfahren zu deren Herstellung.
NO972303L (no) Intravenöse lubeluzollösninger
ATE56743T1 (de) Brennfluessigkeit.
Senczuk et al. Toxicodynamic properties of toluidines. Part V. Methaemoglobin-genic action of toluidines.